https://www.selleckchem.com/products/erastin.html
Forty-two trials were included for analysis. The network meta-analysis of pain showed that hylan G-F 20 may be equivalent to IACS in the short-term, but by 6 months the benefit relative to IACS was statistically significant, standardized mean difference (95% credible interval) -0.13 (-0.26, -0.01). There were no statistical differences in adverse events. Hylan G-F 20 may perform better in relieving pain at 6 months post-injection compared to IACS. Both agents were relatively well tolerated, with no clear differences in safety. Hylan G-F
Like
Comment
Share
